Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells.
OBJECTIVE
This study aimed to determine the long-term survival of 30 dendritic cell (DC) vaccinated patients with metastatic renal cell cancer.


METHODS
Patients were treated with a therapeutic vaccination of pulsed DCs in one of three clinical phase I/II trials during the years 1999 - 2003.


RESULTS
Patients were followed up until 191 months (mean 65 days after DC therapy), when all patients had died. Total response to treatment was 40% with partial remission in 3%, mixed response in 7% and stable disease in 30%. The progressive disease rate was 60%. Long-term survival ranged from 3 to 191 months, with a mean survival of 59 months. Interestingly, patients who were treated previously with another form of immunotherapy showed a significantly improved probability of surviving. Mean long-term survival from the beginning of DC therapy was 21 months (1 to 75 months).


CONCLUSIONS
Patients treated with DC vaccination seem to have a benefit in long-term survival.
Kraemer
Markus
M
Center for Integrated Oncology (CIO), Department of Internal Medicine III, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.
Hauser
Stefan
S
Schmidt-Wolf
Ingo G H
IG
D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014611:Vaccination